Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Chief Admin. and Legal Officer | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,023,643 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 43,212 · Balance 1,038,054 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 14,411 · Balance 1,023,643 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 115,812 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · derivative · entry 4 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,812 Underlying: Class A Common Stock · 115,812 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 14,267 | $3.84 | $54,785.28 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,355 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 42,780 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,037,622 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 17:29 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 203,125 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000062 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,842 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 14,411 | $3.84 | $55,338.24 |
DisclosureSEC source: 0002064832-26-000086 · form4a.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,643 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 16:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 43,212 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000086 · form4a.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038,054 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 13,510 | $3.73 | $50,392.30 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 4 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,717 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 12,761 | $3.73 | $47,598.53 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,227 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 24,428 | $3.73 | $91,116.44 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 817,988 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 4,043 | $3.73 | $15,080.39 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,416 Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 17:44 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 9,022 | $2.99 | $26,948.71 |
DisclosureSEC source: 0001062993-25-011161 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,459 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.945 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 17:44 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 142,379 | $2.91 | $413,625.23 |
DisclosureSEC source: 0001062993-25-011161 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,437 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.815 to $2.98, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 17:44 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 100,863 | $2.82 | $284,716.08 |
DisclosureSEC source: 0001062993-25-011161 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,058 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.74 to $2.875, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 167,625 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003226 · form4.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,625 Underlying: Class A Common Stock · 167,625 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 162,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003226 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 594,195 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 16, 2025 Filed Feb 19, 2025 19:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 646 | $3.70 | $2,390.20 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 4 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,148 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,070 | $3.70 | $11,359.00 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,794 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 22,178 | $3.70 | $82,058.60 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,864 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 19:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 11,230 | $3.70 | $41,551.00 |
DisclosureSEC source: 0001062993-25-002932 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,042 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,974 | $2.80 | $5,527.20 |
DisclosureSEC source: 0001062993-24-007935 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,272 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 276,737 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004312 · form4.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,737 Underlying: Class A Common Stock · 276,737 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 153,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004312 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,246 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 20:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 646 | $3.48 | $2,248.08 |
DisclosureSEC source: 0001062993-24-003763 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,185 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,643 | $3.68 | $13,406.24 |
DisclosureSEC source: 0001062993-24-003763 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,831 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 20:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 21,516 | $3.68 | $79,178.88 |
DisclosureSEC source: 0001062993-24-003763 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,474 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,339 | $2.13 | $4,982.07 |
DisclosureSEC source: 0001062993-23-008506 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,990 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 331,076 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004891 · form4.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,076 Underlying: Class A Common Stock · 331,076 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 278,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004891 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,329 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:25 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 765 | $2.75 | $2,103.75 |
DisclosureSEC source: 0001062993-23-004059 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,445 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:25 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,635 | $2.92 | $10,614.20 |
DisclosureSEC source: 0001062993-23-004059 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,210 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 18:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,984 | $7.89 | $23,543.76 |
DisclosureSEC source: 0001062993-22-009811 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,845 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 18:53 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 765 | $7.78 | $5,951.70 |
DisclosureSEC source: 0001062993-22-004798 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,829 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:53 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 99,236 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001062993-22-004798 · form4.xml · derivative · entry 3 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,236 Underlying: Class A Common Stock · 99,236 shares Expires 2032-02-15 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:53 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 41,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004798 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,594 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,975 | $19.83 | $39,164.25 |
DisclosureSEC source: 0000899243-21-014959 · doc4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,751 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:43 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 67,444 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001661181-21-000029 · edgar.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,444 Underlying: Class A Common Stock · 67,444 shares Expires 2031-02-16 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:43 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 8,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000029 · edgar.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,726 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 07:56 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 177,310 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-20-000016 · edgar.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,310 Underlying: Class A Common Stock · 177,310 shares Expires 2030-04-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 07:56 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 26,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000016 · edgar.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,918 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 20:05 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 40,600 | Not disclosed Strike: $5.40 | Not disclosed |
DisclosureSEC source: 0001661181-18-000039 · edgar.xml · derivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,600 Underlying: Common Stock · 40,600 shares Expires 2028-02-21 F2 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 20,000 shares of common stock of Organogenesis for $10.95 per share. F1 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 30, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.